GlassScriptPhysician profile
Mary A Madden
NPI 1083720957
$3,575.32
in general payments reported to CMS, 2019-2025
25 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $880 · 2021: $441 · 2022: $312 · 2023: $206 · 2024: $446 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.18 | 2019-2025 | |
| Novo Nordisk INC | $458.06 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $362.67 | 2019-2025 | |
| Pfizer INC. | $354.44 | 2019-2023 | |
| Lilly USA, LLC | $254.34 | 2019-2025 | Mounjaro, Zepbound |
| Heartflow, INC. | $201.20 | 2024 | |
| Novartis Pharmaceuticals Corporation | $195.11 | 2019-2020 | |
| Amgen INC. | $169.21 | 2022-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $167.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $91.67 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.80 | 2020-2025 | Xifaxan |
| Exact Sciences Corporation | $79.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $72.64 | 2020-2025 | Tirosint, Flector, Licart |
| Esperion Therapeutics, INC. | $43.48 | 2022-2024 | Nexletol |
| Dexcom, INC. | $29.83 | 2024 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $29.44 | 2023 | Yupelri |
| Acella Pharmaceuticals, LLC | $28.99 | 2024-2025 | NP Thyroid 60 |
| Kowa Pharmaceuticals America, INC. | $24.92 | 2020 | |
| Glaxosmithkline, LLC. | $23.93 | 2023 | Trelegy Ellipta |
| Redhill Biopharma INC. | $22.91 | 2020 | |
| Genentech USA, INC. | $18.77 | 2019 | |
| Nabriva Therapeutics, Plc | $16.10 | 2021 | |
| Allergan, INC. | $16.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.87 | 2021 | |
| Eisai INC. | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Madden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.